Comparing blood thinners after a heart attack
Part of Heart & circulation clinical trials.
This study compares two ways to lower the chances of another heart attack: taking the standard medicine (clopidogrel) versus taking a combination of aspirin and a lower dose of a blood thinner (rivaroxaban). If you join, you'll be assigned to one of these options to see which works better for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 65 years old and had a heart attack at least a year ago.
- You have heart disease or peripheral artery disease (blocked arteries).
- You have not had a major bleeding problem or an allergy to aspirin or clopidogrel.
- Your kidneys and liver work well enough (no severe kidney or liver disease).
- You are not taking certain other blood thinners or other trial medicines that can interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two common “blood thinner” combinations to prevent problems after a PCI procedure for complex blocked heart arteries. It may help your care team find which combination works better for people with higher-risk artery patterns.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
This Phase 3 trial compares two strategies to prevent blood clots after heart bypass surgery: aspirin alone versus aspirin plus ticagrelor. It aims to see which approach works better and is safer for people whose bypass does not fully restore blood flow.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This trial compares two ways to choose blood thinners after a heart attack in people at high risk for bleeding. One way uses a genetic test to guide the choice, while the other uses a different approach.
Hear when a new Cardiac Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.